Edesa Biotech, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pardeep Nijhawan
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Spy Court Markham ON Canada L3R 5H6
- IPO Date
- Jun 21, 2010
- CIK
- 0001540159
- Website
- edesabiotech.com
- Similar Companies
- Business
- Edesa Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering, advancing, and bringing to market novel therapies for inflammatory and immune-related conditions where significant unmet medical needs exist. The company's lead investigational compound, paridiprubart (EB05), a monoclonal antibody, recently yielded positive results in a Phase 3 clinical study for acute respiratory distress syndrome (ARDS) and is concurrently being evaluated in a U.S. government-funded platform study. Another key candidate, daniluromer (EB01), a topical treatment, has completed a Phase 2b clinical study demonstrating favorable outcomes for chronic allergic contact dermatitis and is now considered Phase 3-ready. Additionally, Edesa is progressing EB06, an anti-CXCL10 monoclonal antibody for vitiligo, which has received regulatory approval for a Phase 2 study in Canada. The company’s innovative approach includes developing monoclonal antibodies that target pathways like TLR4 and CXCL10. Edesa Biotech, Inc. was established in 2015 and maintains its corporate headquarters in Markham, Canada.
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study
Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops
Edesa Biotech Reports Fiscal 1st Quarter 2026 Results
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
Edesa Biotech Reports Fiscal Year 2025 Results
Edesa Biotech Announces Upcoming Conference Schedule
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech Posts Narrower Loss in Q3
Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results
Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
Edesa Biotech Announces Chief Financial Officer Transition
Edesa Biotech Reports Fiscal 1st Quarter 2025 Results
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules